Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

The goal of the NHLBI Catalyze Program is to provide support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates. This specific initiative will support the validation of transformative, multi-use platforms or technologies that can enable significant acceleration and/or transformation in areas such as early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention, or epidemiology related to heart, lung, blood, and sleep (HLBS) disorders. • The program aims to develop translational researchers fluent in product development and entrepreneurship. • Proposed platforms and technologies must have the potential to improve the outlook for HLBS-related diseases and disorders. • Applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention, or epidemiology. • The award ceiling for this opportunity is $350,000.